Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer

Borghaei et al. (Sun,) studied this question.

www.synapsesocial.com/papers/69d7218aef370a38abf50ccc — DOI: https://doi.org/10.1056/nejmoa1507643

Also consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer· 2015 · 8,522 citations
2. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma· 2010 · 15,098 citations
3. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)· 2008 · 29,244 citations
4. Randomized Phase III Trial of Docetaxel Versus Vinorelbine or Ifosfamide in Patients With Advanced Non–Small-Cell Lung Cancer Previously Treated With Platinum-Containing Chemotherapy Regimens· 2000 · 1,372 citations
5. Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial· 2014 · 1,303 citations